insitro adds to team to advance machine learning drug discovery and development efforts

California-based insitro, a machine learning-driven drug discovery and development company, has announced the expansion of its leadership team.

Martha Rook, who has been named chief technical operations officer, has more than 20 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and cell and gene therapy manufacturing.

She joins insitro from Sigilon Therapeutics (Nasdaq: SGTX), where she served as chief technical operations officer and was responsible for the analytics, manufacturing, supply chain and quality organizations. Dr Rook also spent 13 years at MilliporeSigma, where she held a variety of roles, ultimately serving as vice president and head of the Gene Editing and Novel Modalities Business, and led a team developing and providing tools and services for cell and gene therapies from discovery to manufacturing.